Report of the Paris consensus meeting on expanded criteria donors in liver transplantation

Liver Transplantation

Volumn 14, Issue 12, 2008, Pages 1694-1707

  Durand, François ^a   Renz, John F ^b   Alkofer, Barbara ^a   Burra, Patrizia ^c   Clavien, Pierre Alain ^d   Porte, Robert J ^e   Freeman, Richard B ^f   Belghiti, Jacques ^a  

^a BEAUJON HOSPITAL   (France)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

^f TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASIA; BACTERIAL INFECTION; BRAIN DEATH; COLD ISCHEMIA; CONSENSUS DEVELOPMENT; DONOR SELECTION; EMERGENCY SURGERY; EUROPE; FAMILIAL AMYLOID POLYNEUROPATHY; FRANCE; GRAFT RECIPIENT; HEART DEATH; HUMAN; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; ORGAN DONOR; ORGAN PRESERVATION; PRIORITY JOURNAL; REPERFUSION; REVIEW; RISK FACTOR; STEATOSIS; SURGICAL TECHNIQUE; TERMINAL DISEASE; UNITED STATES; CONSENSUS; DONOR; ETHICS; METHODOLOGY; PRACTICE GUIDELINE; STANDARD;

PRESERVATION SOLUTION;

COLD ISCHEMIA; CONSENSUS; DONOR SELECTION; HUMANS; LIVER TRANSPLANTATION; ORGAN PRESERVATION SOLUTIONS; PARIS; PRACTICE GUIDELINES AS TOPIC; TISSUE DONORS;

EID: 58249084969     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21668     Document Type: Review

References (123)

1. Francoz C, Belghiti J, Durand F. Indications of liver transplantation in patients with complications of cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:175-190.
2. Neuberger J. Developments in liver transplantation. Gut 2004;53:759-768.
3. Adam R, Cailliez V, Majno P, Karam V, McMaster P, Caine RY, et al. Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study. Lancet 2000;356:621-627.
4. Foster R, Zimmerman M, Trotter JF. Expanding donor options: marginal, living, and split donors. Clin Liver Dis 2007;11:417-429.
5. Barshes NR, Horwitz IB, Franzini L, Vierling JM, Goss JA. Waitlist mortality decreases with increased use of extended criteria donor liver grafts at adult liver transplant centers. Am J Transplant 2007;7:1265-1270.
6. Tector AJ, Mangus RS, Chestovich P, Vianna R, Fridell JA, Milgrom ML, et al. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg 2006;244:439-450.
7. Alkofer B, Samstein B, Guarrera JV, Kin C, Jan D, Bellemare S, et al. Extended-donor criteria liver allografts. Semin Liver Dis 2006;26:221-233.
8. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783-790.
9. Workgroup on expanded criteria organs for liver transplantation. Liver Transpl 2005;11:1184-1192.
10. Lucidi V, Lemye AC, Baire L, Buggenhout A, Hoang AD, Loi P, et al. Use of marginal donors for liver transplantation: a single-center experience within the Eurotransplant patient-driven allocation system. Transplant Proc 2007;39:2668-2671.
11. Silberhumer GR, Pokorny H, Hetz H, Herkner H, Rasoul-Rockenschaub S, Soliman T, et al. Combination of extended donor criteria and changes in the Model for End-Stage Liver Disease score predict patient survival and primary dysfunction in liver transplantation: a retrospective analysis. Transplantation 2007;83:588-592.
12. Renz JF, Kin C, Kinkhabwala M, Jan D, Varadarajan R, Goldstein M, et al. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg 2005;242:556-563; discussion 563-555.
13. Cameron A, Busuttil RW. AASLD/ILTS transplant course: is there an extended donor suitable for everyone? Liver Transpl 2005;11:S2-S5.
14. United Network for Organ Sharing. Available at: http://www.unos.org. Accessed September 2008.
15. Wood KE, Becker BN, McCartney JG, D'Alessandro AM, Coursin DB. Care of the potential organ donor. N Engl J Med 2004;351:2730-2739.
16. Wilhelm MJ, Pratschke J, Laskowski IA, Paz DM, Tilney NL. Brain death and its impact on the donor heart - lessons from animal models. J Heart Lung Transplant 2000;19:414-418.
17. Boulard G, Guiot P, Pottecher T, Tenaillon A. Management of subjects in a state of brain death and the preservation of organs [in French]. Ann Fr Anesth Reanim 2005;24:836-843.
18. Lutz-Dettinger N, de Jaeger A, Kerremans I. Care of the potential pediatric organ donor. Pediatr Clin North Am 2001;48:715-749.
19. Rosendale JD, Kauffman HM, McBride MA, Chabalewski FL, Zaroff JG, Garrity ER, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation 2003;75:1336-1341.
20. Salim A, Vassiliu P, Velmahos GC, Sava J, Murray JA, Belzberg H, et al. The role of thyroid hormone administration in potential organ donors. Arch Surg 2001;136: 1377-1380.
21. Khan AW, Fuller BJ, Shah SR, Davidson BR, Rolles K. A prospective randomized trial of N-acetyl cysteine administration during cold preservation of the donor liver for transplantation. Ann Hepatol 2005;4:121-126.
22. Zhang SJ, Shi JH, Tang Z, Wu Y, Chen S. Protective effects of glycine pretreatment on brain-death donor liver. Hepatobiliary Pancreat Dis Int 2005;4:37-40.
23. Singer P, Shapiro H, Cohen J. Brain death and organ damage: the modulating effects of nutrition. Transplantation 2005;80:1363-1368.
24. Piratvisuth T, Tredger JM, Hayllar KA, Williams R. Contribution of true cold and rewarming ischemia times to factors determining outcome after orthotopic liver transplantation. Liver Transpl Surg 1995;1:296-301.
25. Cameron AM, Ghobrial RM, Yersiz H, Farmer DG, Lipshutz GS, Gordon SA, et al. Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg 2006;243:748-753; discussion 753-745.
26. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994;20:829-838.
27. European Liver Transplant Registry. Available at: http://www.eltr.org. Accessed September 2008.
28. Yersiz H, Shaked A, Olthoff K, Imagawa D, Shackleton C, Martin P, et al. Correlation between donor age and the pattern of liver graft recovery after transplantation. Transplantation 1995;60:790-794.
29. Organ Procurement and Transplantation Network. Available at: http://www.optn.org/ar2007/904a_li.pdf. Accessed September 2008.
30. Belzer FO, Southard JH. Organ preservation and transplantation. Prog Clin Biol Res 1986;224:291-303.
31. Cavallari A, Cillo U, Nardo B, Filipponi F, Gringeri E, Montalti R, et al. A multicenter pilot prospective study comparing Celsior and University of Wisconsin preserving solutions for use in liver transplantation. Liver Transpl 2003;9:814-821.
32. Belzer FO, D'Alessandro AM, Hoffmann RM, Knechtle SJ, Reed A, Pirsch JD, et al. The use of UW solution in clinical transplantation. A 4-year experience. Ann Surg 1992; 215:579-583; discussion 584-575.
33. Ben Mosbah I, Massip-Salcedo M, Fernandez-Monteiro I, Xaus C, Bartrons R, Boillot O, et al. Addition of adenosine monophosphate-activated protein kinase activators to University of Wisconsin solution: a way of protecting rat steatotic livers. Liver Transpl 2007;13:410-425.
34. Howden BO, Jablonski P. Liver preservation: a comparison of Celsior to colloid-free University of Wisconsin solution. Transplantation 2000;70:1140-1142.
35. Feng L, Zhao N, Yao X, Sun X, Du L, Diao X, et al. Histidine-tryptophan-ketoglutarate solution vs. University of Wisconsin solution for liver transplantation: a systematic review. Liver Transpl 2007;13:1125-1136.
36. Ben Mosbah I, Rosello-Catafau J, Franco-Gou R, Abdennebi HB, Saidane D, Ramella-Virieux S, et al. Preservation of steatotic livers in IGL-1 solution. Liver Transpl 2006;12:1215-1223.
37. Pedotti P, Cardillo M, Rigotti P, Gerunda G, Merenda R, Cillo U, et al. A comparative prospective study of two available solutions for kidney and liver preservation. Transplantation 2004;77:1540-1545.
38. Eghtesad B, Aucejo F, Fung JJ. Preservation solutions in liver transplantation: what are the options? Liver Transpl 2006;12:196-198.
39. Verran D, Kusyk T, Painter D, Fisher J, Koorey D, Strasser S, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003;9:500-505.
40. McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien PA. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg 2007;246:940-946; discussion 946-948.
41. Fishbein TM, Fiel MI, Emre S, Cubukcu O, Guy SR, Schwartz ME, et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997;64: 248-251.
42. Frankel WL, Tranovich JG, Salter L, Bumgardner G, Baker P. The optimal number of donor biopsy sites to evaluate liver histology for transplantation. Liver Transpl 2002;8:1044-1050.
43. Urena MA, Ruiz-Delgado FC, Gonzalez EM, Segurola CL, Romero CJ, Garcia IG, et al. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program. Transplant Proc 1998;30:3288-3291.
44. Zamboni F, Franchello A, David E, Rocca G, Ricchiuti A, Lavezzo B, et al. Effect of macrovesicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. Clin Transplant 2001;15:53-57.
45. Imber CJ, St Peter SD, Lopez I, Guiver L, Friend PJ. Current practice regarding the use of fatty livers: a trans-Atlantic survey. Liver Transpl 2002;8:545-549.
46. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001;21:105-113.
47. Ploeg RJ, D'Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, et al. Risk factors for primary dysfunction after liver transplantation - a multivariate analysis. Transplantation 1993;55:807-813.
48. D'Alessandro AM, Kalayoglu M, Sollinger HW, Hoffmann RM, Reed A, Knechtle SJ, et al. The predictive value of donor liver biopsies on, the development of primary non-function after orthotopic liver transplantation. Transplant Proc 1991:23:1536-1537.
49. Canelo R, Braun F, Sattler B, Klinge B, Lorf T, Ramadori G, et al. Is a fatty liver dangerous for transplantation? Transplant Proc 1999;31:414-415.
50. Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007;356:1545-1559.
51. Taub R. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 2004;5:836-847.
52. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
53. Mutimer DJ, Gunson B, Chen J, Berenguer J, Neuhaus P, Castaing D, et al. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation 2006;81:7-14.
54. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-252.
55. Jimenez Romero C, Moreno Gonzalez E, Colina Ruiz F, Palma Carazo F, Loinaz Segurola C, Rodriguez Gonzalez F, et al. Use of octogenarian livers safely expands the donor pool. Transplantation 1999;68:572-575.
56. Nardo B, Masetti M, Urbani L, Caraceni P, Montalti R, Filipponi F, et al. Liver transplantation from donors aged 80 years and over: pushing the limit. Am J Transplant 2004;4:1139-1147.
57. Diamond IR, Fecteau A, Millis JM, Losanoff JE, Ng V, Anand R, et al. Impact of graft type on outcome in pediatric liver transplantation: a report from Studies of Pediatric Liver Transplantation (SPLIT). Ann Surg 2007;246: 301-310.
58. Vargas HE, Laskus T, Wang LF, Lee R, Radkowski M, Dodson F, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999;117:149-153.
59. Velidedeoglu E, Desai NM, Campos L, Olthoff KM, Shaked A, Nunes F, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation 2002;73:582-587.
60. Freeman RB, Giatras I, Falagas ME, Supran S, O'Connor K, Bradley J, et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation 1999; 68:1107-1111.
61. Cerutti E, Stratta C, Romagnoli R, Serra R, Lepore M, Fop F, et al. Bacterial- and fungal-positive cultures in organ donors: clinical impact in liver transplantation. Liver Transpl 2006;12:1253-1259.
62. Lumbreras C, Sanz F, Gonzalez A, Perez G, Ramos MJ, Aguado JM, et al. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. Clin Infect Dis 2001;33:722-726.
63. Lopez-Navidad A, Domingo P, Caballero F, Gonzalez C, Santiago C. Successful transplantation of organs retrieved from donors with bacterial meningitis. Transplantation 1997;64:365-368.
64. Kauffman HM, McBride MA, Cherikh WS, Spain PC, Delmonico FL. Transplant tumor registry: donors with central nervous system tumors. Transplantation 2002;73: 579-582.
65. Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation 2000;70:1747-1751.
66. Buell JF, Alloway RR, Steve Woodle E, Trofe J, Sethuraman G, Hanaway MJ, et al. How can donors with a previous malignancy be evaluated? Donors with central nervous system malignancies: are they truly safe? J Hepatol 2006;45:503-507.
67. Criteria for preventing the transmission of neoplastic disease in organ donation. Available at: http://ec.europa.eu/health. Accessed September 2008.
68. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-537.
69. Burroughs AK, Sabin CA, Rolles K, Delvart V, Karam V, Buckels J, et al. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet 2006;367:225-232.
70. Wilms C, Walter J, Kaptein M, Mueller L, Lenk C, Sterneck M, et al. Long-term outcome of split liver transplantation using right extended grafts in adulthood: a matched pair analysis. Ann Surg 2006;244:865-872; discussion 872-863.
71. Renz JF, Emond JC, Yersiz H, Ascher NL, Busuttil RW. Split-liver transplantation in the United States: outcomes of a national survey. Ann Surg 2004;239:172-181.
72. Burdelski MM, Rogiers X. What lessons have we learned in pediatric liver transplantation? J Hepatol 2005;42:28-33.
73. Sampietro R, Goffette P, Danse E, De Reyck C, Roggen F, Ciccarelli O, et al. Extension of the adult hepatic allograft pool using split liver transplantation. Acta Gastroenterol Belg 2005;68:369-375.
74. Sommacale D, Farges O, Ettorre GM, Lebigot P, Sauvanet A, Marty J, et al. In situ split liver transplantation for two adult recipients. Transplantation 2000;69:1005-1007.
75. Humar A, Ramcharan T, Sielaff TD, Kandaswamy R, Gruessner RW, Lake JR, et al. Split liver transplantation for two adult recipients: an initial experience. Am J Transplant 2001;1:366-372.
76. Merion RM, Rush SH, Dykstra DM, Goodrich N, Freeman RB Jr, Wolfe RA. Predicted lifetimes for adult and pediatric split liver versus adult whole liver transplant recipients. Am J Transplant 2004;4:1792-1797.
77. Noujaim HM, Gunson B, Mayer DA, Mirza DF, Buckels JA, Candinas D, et al. Worth continuing doing ex situ liver graft splitting? A single-center analysis. Am J Transplant 2003;3:318-323.
78. Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008; 8:958-976.
79. Liu CL, Fan ST, Lo CM, Wei WI, Chan SC, Yong BH, et al. Operative outcomes of adult-to-adult right lobe live donor liver transplantation: a comparative study with cadaveric whole-graft liver transplantation in a single center. Ann Surg 2006;243:404-410.
80. Chan SC, Fan ST, Lo CM, Liu CL, Wong J. Toward current standards of donor right hepatectomy for adult-to-adult live donor liver transplantation through the experience of 200 cases. Ann Surg 2007;245:110-117.
81. Berg CL, Gillespie BW, Merion RM, Brown RS Jr, Abecassis MM, Trotter JF, et al. Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology 2007;133:1806-1813.
82. Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 2007;94:78-86.
83. Garcia-Retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004;40:699-707.
84. Terrault NA, Shiffman ML, Lok AS, Saab S, Tong L, Brown RS Jr, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007;13:122-129.
85. Trotter JF, Wachs M, Everson GT, Kam I. Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 2002;346:1074-1082.
86. Olthoff KM, Merion RM, Ghobrial RM, Abecassis MM, Fair JH, Fisher RA, et al. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL consortium. Ann Surg 2005;242:314-323; discussion 323-325.
87. Pomposelli JJ, Verbesey J, Simpson MA, Lewis WD, Gordon FD, Khettry U, et al. Improved survival after live donor adult liver transplantation (LDALT) using right lobe grafts: program experience and lessons learned. Am J Transplant 2006;6:589-598.
88. Concejero A, Chen CL, Wang CC, Wang SH, Lin CC, Liu YW, et al. Living donor liver transplantation for hepatocellular carcinoma: a single-center experience in Taiwan. Transplantation 2008;85:398-406.
89. Hwang S, Lee SG, Lee YJ, Sung KB, Park KM, Kim KH, et al. Lessons learned from 1,000 living donor liver transplantations in a single center: how to make living donations safe. Liver Transpl 2006;12:920-927.
90. Fan ST. Live donor liver transplantation in adults. Transplantation 2006;82:723-732.
91. Trotter JF, Campsen J, Bak T, Wachs M, Forman L, Everson G, et al. Outcomes of donor evaluations for adult-to-adult right hepatic lobe living donor liver transplantation. Am J Transplant 2006;6:1882-1889.
92. Kawasaki S. Left lobe living donor liver transplantation: technical considerations. Transplant Proc 2003; 35:952.
93. Soejima Y, Taketomi A, Ikegami T, Yoshizumi T, Uchiyama H, Yamashita Y, et al. Living donor liver transplantation using dual grafts from two donors: a feasible option to overcome small-for-size graft problems? Am J Transplant 2008;8:887-892.
94. Boillot O, Delafosse B, Mechet I, Boucaud C, Pouyet M. Small-for-size partial liver graft in an adult recipient; a new transplant technique. Lancet 2002;359:406-407.
95. Chen Z, Yan L, Li B, Zeng Y, Wen T, Zhao J, et al. Successful adult-to-adult living donor liver transplantation combined with a cadaveric split left lateral segment. Liver Transpl 2006;12:1557-1559.
96. Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77:64-71.
97. Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 2007;7:2597-2604.
98. Inomata Y, Zeledon ME, Asonuma K, Okajima H, Takeichi T, Ishiko T, et al. Whole-liver graft without the retrohepatic inferior vena cava for sequential (domino) living donor liver transplantation. Am J Transplant 2007;7: 1629-1632.
99. Takei Y, Gono T, Yazaki M, Ikeda S, Ikegami T, Hashikura Y, et al. Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver. Liver Transpl 2007;13:215-218.
100. Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 2005;352: 2356.
101. Familial Amyloidotic Polyneuropathy World Transplant Registry. Available at: http://www.fapwtr.org. Accessed September 2008.
102. Deshpande R, Heaton N. Can non-heart-beating donors replace cadaveric heart-beating liver donors? J Hepatol 2006;45:499-503.
103. Suarez F, Otero A, Solla M, Arnal F, Lorenzo MJ, Marini M, et al. Biliary complications after liver transplantation from Maastricht category-2 non-heart-beating donors. Transplantation 2008;85:9-14.
104. Abt PL, Desai NM, Crawford MD, Forman LM, Markmann JW, Olthoff KM, et al. Survival following liver transplantation from non-heart-beating donors. Ann Surg 2004; 239:87-92.
105. Muiesan P, Girlanda R, Jassem W, Melendez HV, O'Grady J, Bowles M, et al. Single-center experience with liver transplantation from controlled non-heart beating donors: a viable source of grafts. Ann Surg 2005;242: 732-738.
106. Monbaliu D, Crabbe T, Roskams T, Fevery J, Verwaest C, Pirenne J. Livers from non-heart-beating donors tolerate short periods of warm ischemia. Transplantation 2005; 79:1226-1230.
107. Net M, Valero R, Almenara R, Barros P, Capdevila L, Lopez-Boado MA, et al. The effect of normothermic recirculation is mediated by ischemic preconditioning in NHBD liver transplantation. Am J Transplant 2005;5: 2385-2392.
108. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008;8:419-425.
109. Maluf DG, Edwards EB, Kauffman HM. Utilization of extended donor criteria liver allograft: is the elevated risk of failure independent of the Model for End-Stage Liver Disease score of the recipient? Transplantation 2006;82: 1653-1657.
110. Belghiti J, Noun R, Sauvanet A, Durand F, Aschehoug J, Erlinger S, et al. Transplantation for fulminant and sub-fulminant hepatic failure with preservation of portal and caval flow. Br J Surg 1995;82:986-989.
111. Heidenhain C, Heise M, Jonas S, Ben-Asseur M, Puhl G, Mittler J, et al. Retrograde reperfusion via vena cava lowers the risk of initial nonfunction but increases the risk of ischemic-type biliary lesions in liver transplantation - a randomized clinical trial. Transpl Int 2006;19: 738-748.
112. Polak WG, Porte RJ. The sequence of revascularization in liver transplantation: it does make a difference. Liver Transpl 2006;12:1566-1570.
113. Noun R, Sauvanet A, Belghiti J. Appraisal of the order of revascularization in human liver grafting: a controlled study. J Am Coll Surg 1997;185:70-73.
114. Dahm F, Georgiev P, Clavien PA. Small-for-size syndrome after partial liver transplantation: definition, mechanisms of disease and clinical implications. Am J Transplant 2005;5:2605-2610.
115. Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, et al. Effect of intraportal infusion to improve small for size graft injury in living donor adult liver transplantation. Transpl Int 2005;18:923-928.
116. Camus C, Lavoue S, Gacouin A, Le Tulzo Y, Lorho R, Boudjema K, et al. Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation. Intensive Care Med 2006;32:1817-1825.
117. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005;42:448-456.
118. Cameron AM, Ghobrial RM, Hiatt JR, Carmody IC, Gordon SA, Farmer DG, et al. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006;244:563-571.
119. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384-393; discussion 393-384.
120. Arenas JI, Vargas HE, Rakela J. The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl 2003;9:S48-S51.
121. Saab S, Ghobrial RM, Ibrahim AB, Kunder G, Durazo F, Han S, et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. Am J Transplant 2003;3:1167-1172.
122. Saab S, Chang AJ, Comulada S, Geevarghese SK, Anselmo RD, Durazo F, et al. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl 2003;9:1053-1061.
123. Rosen HR, Prieto M, Casanovas-Taltavull T, Cuervas-Mons V, Guckelberger O, Muiesan P, et al. Validation and refinement of survival models for liver retransplantation. Hepatology 2003;38:460-469.